Montelukast and Coronavirus Disease 2019: A Scoping Review
| Autor: | Mostafa Qorbani, Samin Sharafian, Marzieh Tavakol, Sana Salekmoghadam, Niusha Sharifinejad |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Cyclopropanes
Drug medicine.medical_specialty Coronavirus disease 2019 (COVID-19) medicine.drug_class media_common.quotation_subject medicine.medical_treatment Acetates Sulfides Antiviral Agents Therapeutic approach medicine Humans Immunology and Allergy Intensive care medicine Montelukast Asthma media_common SARS-CoV-2 business.industry COVID-19 medicine.disease COVID-19 Drug Treatment Clinical trial Treatment Outcome Quinolines Medicine Leukotriene Antagonists Leukotriene D4 receptor Antiviral drug business Adjuvant medicine.drug |
| Zdroj: | Iranian Journal of Allergy, Asthma and Immunology, Vol 20, Iss 4 (2021) |
| ISSN: | 1735-5249 1735-1502 |
| Popis: | Coronavirus disease 2019 (COVID-19) is an emerging worldwide issue, that has affected a large number of people around the world. So far, many studies have aimed to develop a therapeutic approach against COVID-19. Montelukast (MK) is a safe asthma controller drug, which is considered as a potential antiviral drug for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This review has a systematic approach to investigate the reports on the use of MK as a part of treatment or a prophylactic agent in COVID-19. The search was conducted in PubMed, Web of Science, and Scopus databases and yielded 35 studies containing the influence of MK on SARS-CoV-2. Ultimately, MK appears to be worth being used as an adjuvant therapeutic and prophylactic drug against SARS-CoV-2. Nevertheless, more clinical trials are required to accurately investigate its effectiveness. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|